FDA
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) PT Raised to $104 at Clear Street
-
-
-
-
-
-
-
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) and Takeda (TAK) Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
-
-
-
-
-
-
-
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
-
-
-
-
-
-
-
Alpha Cognition Announces Change of CFO, Grant of Stock Options and Addition to the Board of Directors
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program
-
322,088 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

